Amgen Ropes Second M&A Deal Of 2021 In Rodeo Buyout

 
• By Joseph Haas

Deal snapshot: Rodeo’s preclinical work in modulating the 15-PDGH enzyme may yield novel regenerative therapies for inflammation, Amgen says, including GI and post-bone marrow transplant indications.

Businessman comparing two documents, neutral background
With its Rodeo acquisition, Amgen has two M&A deals so far in 2021

More from Deals

More from Business